Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical parameters for evaluating biological response modifier therapy.

T J Hamblin1

  • 1Department of Haematology, Royal Victoria Hospital, Bournemouth, UK.

European Journal of Cancer & Clinical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problems of Anticoagulant Control-II, Which Test?

Bristol medico-chirurgical journal (1963)·2017
Same author

CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

Leukemia & lymphoma·2016
Same author

Reading for Pleasure: More worlds per pound.

British medical journal·2010
Same author

The immunodeficiency of chronic lymphocytic leukaemia.

British medical bulletin·2008
Same author

Chronic lymphocytic leukaemia.

Lancet (London, England)·2008
Same author

Chronic lymphocytic leukaemia: clinical translations of biological features.

Current topics in microbiology and immunology·2005
Same journal

The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer.

European journal of cancer & clinical oncology·1989
Same journal

Nutritional factors and cancers of the breast, endometrium and ovary.

European journal of cancer & clinical oncology·1989
Same journal

Reproductive factors and cancers of the breast, ovary and endometrium.

European journal of cancer & clinical oncology·1989
Same journal

Multiple primary cancers of the breast, endometrium and ovary.

European journal of cancer & clinical oncology·1989
Same journal

Cancers of the breast, endometrium and ovary: geographic correlations.

European journal of cancer & clinical oncology·1989
Same journal

Hormone replacement therapy in women treated for breast cancer.

European journal of cancer & clinical oncology·1989
See all related articles

Cancer treatment evaluation traditionally focuses on complete response. However, stable disease or slower progression, potentially enhanced by biological response modifiers, may also significantly improve patient survival and quality of life.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer response evaluation typically defines outcomes as complete response, partial response, stable disease, or progressive disease.
  • Chemotherapy benefits, in terms of survival, are primarily observed in patients achieving complete response.
  • Patient-centered goals include prolonged survival and good quality of life, beyond just tumor response.

Purpose of the Study:

  • To challenge the conventional focus on complete response in cancer treatment evaluation.
  • To explore the potential of biological response modifiers in controlling minimal residual disease and influencing survival outcomes.
  • To advocate for considering stable disease and slower progression as meaningful indicators of treatment efficacy.

Main Methods:

Related Experiment Videos

  • Review of established cancer response evaluation criteria.
  • Discussion of the role of minimal residual disease and its potential biological control.
  • Conceptual framework for biological response modifiers to enhance tumor control.
  • Emphasis on survival curves as the ultimate measure of treatment effectiveness.

    • Main Results:

    • Complete response to chemotherapy is linked to increased survival, but partial response indicates only drug activity.
    • Tumors can remain dormant, and minimal residual disease after complete response is assumed to be biologically controlled.
    • Biological response modifiers aim to enhance the body's control over tumor load.
    • Stable disease or slower progression may lead to prolonged survival, similar to the concept of "life imprisonment" for cancer.

    Conclusions:

    • Cancer treatment success should be measured by prolonged survival and quality of life, not solely by complete tumor eradication.
    • Stable disease and slower progression, potentially achievable with biological response modifiers, represent valuable treatment outcomes.
    • Survival data are critical for validating the efficacy of interventions that manage, rather than eliminate, cancer.